GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » 3-Year RORE %

VCEL (Vericel) 3-Year RORE % : -83.64% (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Vericel's 3-Year RORE % for the quarter that ended in Sep. 2024 was -83.64%.

The industry rank for Vericel's 3-Year RORE % or its related term are showing as below:

VCEL's 3-Year RORE % is ranked worse than
90.95% of 1370 companies
in the Biotechnology industry
Industry Median: -9.185 vs VCEL: -83.64

Vericel 3-Year RORE % Historical Data

The historical data trend for Vericel's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel 3-Year RORE % Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.45 -65.91 -21.62 85.42 -14.75

Vericel Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.92 -14.75 - -57.81 -83.64

Competitive Comparison of Vericel's 3-Year RORE %

For the Biotechnology subindustry, Vericel's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Vericel's 3-Year RORE % falls into.



Vericel 3-Year RORE % Calculation

Vericel's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.07--0.39 )/( -0.55-0 )
=0.46/-0.55
=-83.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Vericel  (NAS:VCEL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Vericel 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Vericel's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Zerbe Robert L Md director
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Kevin F Mclaughlin director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105